2024-12-13 - Analysis Report
## Teladoc Health Inc (TDOC) Stock Analysis Report

**1. Performance Comparison & Divergence:**

Teladoc Health (TDOC) has significantly underperformed the S&P 500 (VOO) over the analyzed period.  The cumulative return for TDOC is -63.22%, while VOO shows a 122.02% return.  This represents a substantial divergence of -185.2%, placing it near the lower bound of the historical range (-187.9% to 710.7%).  The relative divergence of 0.3 indicates its performance is at the lower end of the historical distribution relative to the S&P 500.

**Company Overview:** Teladoc Health Inc. is a telehealth company providing virtual medical care services.


**2. Recent Price Movement:**

* **Closing Price:** $10.58 (Last Market: $10.39)
* **5-Day Moving Average:** $10.73
* **20-Day Moving Average:** $10.48
* **60-Day Moving Average:** $9.53

The price is currently trading slightly above its 20-day moving average, suggesting a potential short-term uptrend, but below the 5-day moving average indicating recent price decline. The price is also above the 60-day average, indicating a longer-term positive trend.  The difference between the last market price ($10.39) and the closing price ($10.58) does not suggest a significant sudden price change.


**3. Technical Indicators & Expected Return:**

* **RSI:** 62.66 – Suggests the stock is neither overbought nor oversold, indicating a neutral sentiment.
* **PPO:** -0.95 – A negative PPO suggests bearish momentum.
* **20-Day Relative Divergence Change:** -0.2 – Indicates a recent short-term downward trend relative to the S&P 500.
* **Expected Return (2+ years):** 0.0% –  The provided data does not support any significant long-term outperformance of the S&P 500 at this juncture, considering the historical underperformance shown.


**4. Recent Earnings Analysis:**

The provided data reveals a concerning trend in both EPS and revenue:

* **EPS:** Consistently negative EPS across all reported quarters, indicating significant losses.  The magnitude of losses fluctuated, but no clear improvement is evident.
* **Revenue:** Revenue remains relatively stable around $0.64-$0.66 Billion across the reported quarters. The lack of significant revenue growth is noteworthy given the persistent losses.
* **Comparison:**  There's no clear improvement in profitability across quarters. The company consistently fails to achieve positive earnings.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue shows slight fluctuation but remains relatively consistent around $0.65B. The profit margin is high (70-72%), which may appear positive; however, given that the EPS remains heavily negative, a more thorough investigation into the accounting methods and the nature of the "profit margin" is required for a comprehensive understanding.
* **Capital and Profitability:**  Equity shows some fluctuations but appears generally strong. The Return on Equity (ROE) is consistently negative, highlighting the company’s failure to generate profits from its equity base.  The substantial negative ROE values are deeply concerning and suggest significant financial challenges.

**6. News and Recent Issues:**

* No recent earnings news (within the last two days) was included in the provided data.
* Information on recent market outlook, analyst opinions, and performance highlights is missing.  This crucial data is necessary for a comprehensive evaluation.


**7. Overall Analysis:**

Teladoc Health (TDOC) presents a highly bearish picture. The stock has significantly underperformed the S&P 500, showing considerable losses.  Financial statements reveal persistent negative EPS despite relatively stable revenue. The high, yet ultimately meaningless, profit margin in conjunction with the continuously negative ROE, suggests the need for further investigation into the firm's financial reporting practices and the sustainability of its operational model.   Missing information regarding recent news, market outlook, and analyst opinions prevents a fully informed assessment. The currently available data suggests a high-risk investment with limited short-term prospects and uncertain long-term potential unless substantial changes to its operations and financial performance are undertaken and demonstrated.  Further research and due diligence are strongly recommended before considering any investment in TDOC.


**8. Disclaimer:** This analysis is based solely on the provided data.  It does not constitute financial advice.  Independent research and consultation with a financial advisor are crucial before making any investment decisions.  Missing data points significantly limit the scope and accuracy of this analysis.
